CY1123954T1 - Χρηση μικροβιακων κοινοτητων για την υγεια των ανθρωπων και των ζωων - Google Patents
Χρηση μικροβιακων κοινοτητων για την υγεια των ανθρωπων και των ζωωνInfo
- Publication number
- CY1123954T1 CY1123954T1 CY20201100950T CY201100950T CY1123954T1 CY 1123954 T1 CY1123954 T1 CY 1123954T1 CY 20201100950 T CY20201100950 T CY 20201100950T CY 201100950 T CY201100950 T CY 201100950T CY 1123954 T1 CY1123954 T1 CY 1123954T1
- Authority
- CY
- Cyprus
- Prior art keywords
- human
- animal health
- mixture
- microbial communities
- bacteria
- Prior art date
Links
- 230000000813 microbial effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 241000894006 Bacteria Species 0.000 abstract 2
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004151 fermentation Effects 0.000 abstract 1
- 238000000855 fermentation Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/26—Means for regulation, monitoring, measurement or control, e.g. flow regulation of pH
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/30—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration
- C12M41/34—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration of gas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/513—Adolescentes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Sustainable Development (AREA)
- Physiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε ένα μίγμα βακτηρίων που ανήκουν σε τουλάχιστον 6 ή 7 διαφορετικά και ειδικά βακτηριακά είδη κατά προτίμηση για χρήση στην πρόληψη ή θεραπεία γαστρεντερικών διαταραχών. Κατά προτίμηση, το εν λόγω μίγμα βακτηρίων αναπτύσσεται μαζί σε έναν αντιδραστήρα ζύμωσης πριν από τη χορήγηση του εν λόγω μίγματος σε ένα υποκείμενο με σκοπό την πρόληψη ή τη θεραπεία της εν λόγω διαταραχής.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16154288 | 2016-02-04 | ||
PCT/EP2017/052422 WO2017134240A1 (en) | 2016-02-04 | 2017-02-03 | Use of microbial communities for human and animal health |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1123954T1 true CY1123954T1 (el) | 2022-03-24 |
Family
ID=55310719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100950T CY1123954T1 (el) | 2016-02-04 | 2020-10-08 | Χρηση μικροβιακων κοινοτητων για την υγεια των ανθρωπων και των ζωων |
Country Status (24)
Country | Link |
---|---|
US (7) | US11096971B2 (el) |
EP (3) | EP3411052B8 (el) |
JP (3) | JP7016112B2 (el) |
KR (1) | KR20180127972A (el) |
CN (2) | CN108712906B (el) |
AU (2) | AU2017216285B2 (el) |
BR (1) | BR112018015097A2 (el) |
CA (1) | CA3011083A1 (el) |
CY (1) | CY1123954T1 (el) |
DK (2) | DK3639834T3 (el) |
ES (2) | ES2824536T3 (el) |
FI (1) | FI3639834T3 (el) |
HK (1) | HK1257070A1 (el) |
HR (1) | HRP20231182T1 (el) |
HU (2) | HUE051114T2 (el) |
IL (3) | IL293486B2 (el) |
LT (2) | LT3411052T (el) |
MX (1) | MX2018009539A (el) |
PL (2) | PL3639834T3 (el) |
PT (1) | PT3639834T (el) |
RS (2) | RS60918B1 (el) |
RU (2) | RU2758387C2 (el) |
SI (2) | SI3639834T1 (el) |
WO (1) | WO2017134240A1 (el) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2964480A1 (en) | 2014-10-31 | 2016-05-06 | Whole Biome Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
LT3411052T (lt) | 2016-02-04 | 2021-01-11 | Universiteit Gent | Mikrobinių bendrijų naudojimas žmogaus ir gyvūno sveikatos pagerinimui |
EP3423093A4 (en) * | 2016-03-04 | 2019-11-13 | The Regents of The University of California | MICROBIAL CONSORTIUM AND USES THEREOF |
WO2018145082A1 (en) * | 2017-02-06 | 2018-08-09 | New York University | Methods and compositions for treating and diagnosing pancreatic cancers |
CN107384828B (zh) * | 2017-08-22 | 2020-06-16 | 中国农业科学院农产品加工研究所 | 阿克曼氏粘细菌培养基及其制备方法 |
EP3675882A4 (en) | 2017-08-30 | 2021-07-28 | Pendulum Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS |
WO2019098810A2 (ko) * | 2017-11-20 | 2019-05-23 | 경희대학교 산학협력단 | 신규 유산균 및 이의 용도 |
KR102250597B1 (ko) | 2017-11-20 | 2021-05-11 | 경희대학교 산학협력단 | 신규 유산균 및 이의 용도 |
WO2019199895A1 (en) | 2018-04-10 | 2019-10-17 | Siolta Therapeutics, Inc. | Microbial consortia |
CN112292141A (zh) * | 2018-04-13 | 2021-01-29 | 医学生命探索有限公司 | 产生长链双羧基脂肪酸(lcdfa)的微生物及其用途 |
WO2019211469A1 (en) * | 2018-05-04 | 2019-11-07 | 4D Pharma Research Limited | Simulated intestinal environment |
CA3106315A1 (en) * | 2018-07-19 | 2020-01-23 | Pendulum Therapeutics, Inc. | Methods and compositions for microbial engraftment |
US11859214B1 (en) | 2018-08-17 | 2024-01-02 | The Government Of The United States, As Represented By The Secretary Of The Army | Automated system for simulating the human lower gastrointestinal tract |
EP3870691A4 (en) * | 2018-09-13 | 2022-09-07 | Xbiome Inc. | METHODS AND COMPOSITIONS FOR TREATING GASTROINTESTINAL AND INFLAMMATORY DISORDERS |
WO2020079026A1 (en) * | 2018-10-15 | 2020-04-23 | Pharmabiome Ag | A method of manufacturing a consortium of bacterial strains |
CN113905749A (zh) * | 2019-01-16 | 2022-01-07 | 德克萨斯大学系统董事会 | 用于治疗免疫检查点抑制剂相关结肠炎的方法和组合物 |
CN110607262B (zh) * | 2019-09-25 | 2022-03-25 | 君维安(武汉)生命科技有限公司 | 一种干预炎性肠炎的益生菌组合物及其筛选方法和应用 |
CN110448577B (zh) * | 2019-09-26 | 2023-06-23 | 青岛农业大学 | 一种溃疡性结肠炎修复益生菌微胶囊制剂 |
CA3153884A1 (en) | 2019-10-07 | 2021-04-15 | Nikole KIMES | Therapeutic pharmaceutical compositions |
WO2021072322A1 (en) * | 2019-10-09 | 2021-04-15 | Mayo Foundation For Medical Education And Research | Treatment for gastrointestinal disorders |
GB201915144D0 (en) * | 2019-10-18 | 2019-12-04 | Multigerm Uk Entpr Ltd | Method of promoting SCFA production by gut microbiota |
CN110916192B (zh) * | 2019-11-25 | 2021-04-13 | 垒途智能教科技术研究院江苏有限公司 | 一种具有防治儿童青少年自闭症的益生菌矿物粉及其应用 |
JP2023507204A (ja) | 2019-12-23 | 2023-02-21 | エボニック オペレーションズ ゲーエムベーハー | グルテン分解のためのプロバイオティクス菌株を含む調製物 |
CN114657083A (zh) * | 2019-12-24 | 2022-06-24 | 顾青 | 一种乳酸菌发酵乳 |
CN111117925B (zh) * | 2020-01-13 | 2021-05-25 | 浙江大学 | Anaerostipes sp B2131菌及其在炎症性肠病中的应用 |
CN111413503A (zh) * | 2020-03-28 | 2020-07-14 | 浙江大学 | 骨桥蛋白作为靶分子在调节高脂饮食引起的肥胖中的应用 |
AU2021254477A1 (en) * | 2020-04-08 | 2022-11-10 | Megmilk Snow Brand Co., Ltd. | Composition for improving gut microbiota |
EP4132550A4 (en) * | 2020-04-08 | 2024-02-28 | Psomagen, Inc. | COMPOSITION AND METHOD FOR ANTIBIOTIC-INDUCING IMBALANCE IN THE MICROBIOTA |
KR102169794B1 (ko) * | 2020-06-24 | 2020-10-27 | 주식회사 엔테로바이옴 | 신규한 피칼리박테리움 프로스니치 균주 eb-fpdk11 및 그의 용도 |
CN111938158B (zh) * | 2020-08-18 | 2023-07-07 | 广东弘元普康医疗科技有限公司 | 一种防止肠道Akkermansia muciniphila菌丰度降低的组合物 |
GB202015687D0 (en) * | 2020-10-02 | 2020-11-18 | Microbiotica Ltd | Therapeutic composition |
CN113215020B (zh) * | 2021-02-22 | 2022-06-17 | 中国科学院微生物研究所 | 罗氏菌mgb-2及其应用 |
CN113214976B (zh) * | 2021-03-29 | 2023-04-14 | 中南大学 | 一种高效筛选嗜酸微生物的装置及其筛选方法 |
BE1029496B1 (fr) * | 2021-08-19 | 2023-01-16 | The Akkermansia Company | Composition comprenant de l'Akkermansia muciniphila pasteurisée pour le traitement ou la prévention des troubles de la contractilité intestinale, en particulier des troubles de l'amplitude de la contractilité duodénale |
AU2022426633A1 (en) | 2021-12-27 | 2024-07-11 | Mrm Health N.V. | Microbial communities |
CN114292781B (zh) * | 2021-12-28 | 2023-08-01 | 中山大学 | 一种长双歧杆菌sysu-02及其应用 |
CN114304380A (zh) * | 2022-01-13 | 2022-04-12 | 合肥河川生物医药科技有限公司 | 普拉梭菌在猪鸡上的应用 |
NL2032642B1 (en) * | 2022-07-29 | 2024-02-06 | Academisch Ziekenhuis Leiden | Improvement of muscle mass and strength |
WO2024049207A1 (ko) * | 2022-08-31 | 2024-03-07 | 주식회사 바이오뱅크힐링 | 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
CN115737687A (zh) * | 2022-10-16 | 2023-03-07 | 新疆医科大学第一附属医院 | 普拉梭菌在制备预防或/和治疗冠心病药物或/和保健品中的应用 |
WO2024123891A1 (en) * | 2022-12-07 | 2024-06-13 | The University Of North Carolina At Chapel Hill Office Of Technology Commercialization | Engineered microorganism compositions and applications thereof |
CN116836880B (zh) * | 2023-07-24 | 2023-11-28 | 中山大学 | 一种普氏梭杆菌及其应用 |
CN116925975B (zh) * | 2023-08-18 | 2024-01-23 | 善恩康生物科技(苏州)有限公司 | 一种Akkermansia muciniphila及其产品和应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0307026D0 (en) * | 2003-03-27 | 2003-04-30 | Rowett Res Inst | Bacterial supplement |
EP2277524B1 (en) * | 2005-09-28 | 2015-11-11 | Nordisk Rebalance A/S | Treatment of IBS using both probiotic bacteria and fermented cereal as treatment effectors |
CN101353633B (zh) * | 2008-06-13 | 2011-12-28 | 浙江工商大学 | Lactobacillus plantarum ZJ316、产生的抗菌肽及其制备与应用 |
GB0903016D0 (en) * | 2009-02-23 | 2009-04-08 | Univ Gent | Method for alleviating intestinal problems and novel bacterial strains therefor |
JP6006117B2 (ja) * | 2009-11-12 | 2016-10-12 | ネステク ソシエテ アノニム | 腸内微生物叢バランス及び健康を促進するための栄養組成物 |
US8445226B2 (en) * | 2010-02-01 | 2013-05-21 | Microbios, Inc. | Process and composition for the manufacture of a microbial-based product |
US20120034198A1 (en) * | 2010-08-04 | 2012-02-09 | Microbios, Inc. | Carriers for storage and delivery of biologics |
WO2012142605A1 (en) * | 2011-04-15 | 2012-10-18 | Samaritan Health Services | Rapid recolonization deployment agent |
CA2848762C (en) | 2011-09-14 | 2021-07-27 | Queen's University At Kingston | Method for treatment of disorders of the gastrointestinal system |
GB201117313D0 (en) * | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
CN103082292B (zh) * | 2011-11-02 | 2015-03-04 | 深圳华大基因研究院 | 罗斯氏菌(Roseburia)在治疗和预防肥胖相关疾病中的应用 |
WO2014075745A1 (en) | 2012-11-19 | 2014-05-22 | Université Catholique de Louvain | Use of akkermansia for treating metabolic disorders |
US8906668B2 (en) * | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
SG10201704035TA (en) | 2012-11-23 | 2017-06-29 | Seres Therapeutics Inc | Synergistic bacterial compositions and methods of production and use thereof |
KR102222273B1 (ko) * | 2013-02-04 | 2021-03-08 | 세레스 테라퓨틱스, 인코포레이티드 | 조성물 및 방법 |
BR112015020819A2 (pt) * | 2013-03-05 | 2017-07-18 | Academisch Ziekenhuis Groningen | uso de faecalibacterium prausnitzii htf-f (dsm 26943) para supressão de inflamação |
AU2014232370B2 (en) | 2013-03-15 | 2018-11-01 | Seres Therapeutics, Inc. | Network-based microbial compositions and methods |
US10058576B2 (en) * | 2013-10-03 | 2018-08-28 | The Trustees Of The University Of Pennsylvania | Compositions and methods comprising a defined microbiome and methods of use thereof |
KR102379658B1 (ko) * | 2013-11-25 | 2022-03-28 | 세레스 테라퓨틱스, 인코포레이티드 | 상승적 박테리아 조성물 및 그것의 생산 방법 및 용도 |
EP2944696A1 (en) | 2014-05-13 | 2015-11-18 | Evonik Degussa GmbH | Method of producing organic compounds |
CA2964480A1 (en) * | 2014-10-31 | 2016-05-06 | Whole Biome Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
LT3411052T (lt) * | 2016-02-04 | 2021-01-11 | Universiteit Gent | Mikrobinių bendrijų naudojimas žmogaus ir gyvūno sveikatos pagerinimui |
-
2017
- 2017-02-03 LT LTEP17703726.4T patent/LT3411052T/lt unknown
- 2017-02-03 BR BR112018015097-5A patent/BR112018015097A2/pt active Search and Examination
- 2017-02-03 RS RS20201197A patent/RS60918B1/sr unknown
- 2017-02-03 SI SI201731419T patent/SI3639834T1/sl unknown
- 2017-02-03 RU RU2018131244A patent/RU2758387C2/ru active
- 2017-02-03 PT PT192129831T patent/PT3639834T/pt unknown
- 2017-02-03 HR HRP20231182TT patent/HRP20231182T1/hr unknown
- 2017-02-03 ES ES17703726T patent/ES2824536T3/es active Active
- 2017-02-03 US US16/068,470 patent/US11096971B2/en active Active
- 2017-02-03 MX MX2018009539A patent/MX2018009539A/es unknown
- 2017-02-03 HU HUE17703726A patent/HUE051114T2/hu unknown
- 2017-02-03 RS RS20230900A patent/RS64782B1/sr unknown
- 2017-02-03 CN CN201780008210.7A patent/CN108712906B/zh active Active
- 2017-02-03 JP JP2018560246A patent/JP7016112B2/ja active Active
- 2017-02-03 PL PL19212983.1T patent/PL3639834T3/pl unknown
- 2017-02-03 LT LTEP19212983.1T patent/LT3639834T/lt unknown
- 2017-02-03 HU HUE19212983A patent/HUE063584T2/hu unknown
- 2017-02-03 DK DK19212983.1T patent/DK3639834T3/da active
- 2017-02-03 IL IL293486A patent/IL293486B2/en unknown
- 2017-02-03 CN CN202310587729.2A patent/CN116570631A/zh active Pending
- 2017-02-03 CA CA3011083A patent/CA3011083A1/en active Pending
- 2017-02-03 ES ES19212983T patent/ES2960781T3/es active Active
- 2017-02-03 EP EP17703726.4A patent/EP3411052B8/en active Active
- 2017-02-03 AU AU2017216285A patent/AU2017216285B2/en active Active
- 2017-02-03 EP EP23182773.4A patent/EP4257194A3/en active Pending
- 2017-02-03 PL PL17703726T patent/PL3411052T3/pl unknown
- 2017-02-03 RU RU2021130638A patent/RU2021130638A/ru unknown
- 2017-02-03 DK DK17703726.4T patent/DK3411052T3/da active
- 2017-02-03 KR KR1020187025280A patent/KR20180127972A/ko active Search and Examination
- 2017-02-03 WO PCT/EP2017/052422 patent/WO2017134240A1/en active Application Filing
- 2017-02-03 EP EP19212983.1A patent/EP3639834B1/en active Active
- 2017-02-03 FI FIEP19212983.1T patent/FI3639834T3/fi active
- 2017-02-03 SI SI201730441T patent/SI3411052T1/sl unknown
-
2018
- 2018-06-28 IL IL260337A patent/IL260337B/en active IP Right Grant
- 2018-12-18 HK HK18116238.8A patent/HK1257070A1/zh unknown
-
2020
- 2020-10-08 CY CY20201100950T patent/CY1123954T1/el unknown
-
2021
- 2021-05-31 IL IL283594A patent/IL283594B/en unknown
- 2021-07-27 US US17/386,266 patent/US20210353694A1/en active Pending
- 2021-10-15 US US17/502,454 patent/US20220023357A1/en active Pending
- 2021-10-15 US US17/502,445 patent/US11491196B2/en active Active
- 2021-10-15 US US17/502,401 patent/US20220072071A1/en active Pending
-
2022
- 2022-01-14 JP JP2022004062A patent/JP7460979B2/ja active Active
- 2022-10-03 US US17/937,553 patent/US11633440B2/en active Active
- 2022-10-03 US US17/937,554 patent/US11596658B2/en active Active
-
2023
- 2023-10-10 AU AU2023248066A patent/AU2023248066A1/en active Pending
- 2023-12-04 JP JP2023204439A patent/JP2024028833A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123954T1 (el) | Χρηση μικροβιακων κοινοτητων για την υγεια των ανθρωπων και των ζωων | |
CY1122191T1 (el) | Βακτηριο για χρηση ως προβιοτικο για διατροφικες και ιατρικες εφαρμογες | |
BR112017011923A2 (pt) | bactéria modificada para tratar doenças associadas com hiperamonemia | |
EA201991643A1 (ru) | Человеческие антитела к токсину гемолизину а s.aureus | |
CY1120354T1 (el) | Αναστολεις ακυλοτρανσφερασης της διακυλογλυκερολης 2 για χρηση στη θεραπεια μεταβολικων και συγγενων διαταραχων | |
WO2016070051A3 (en) | Combination therapy for treatment of disease | |
CY1120026T1 (el) | Κρενολανιμπη για την θεραπεια μεταλλαγμενων me flt3 πολλαπλασιαστικων διαταραχων | |
CY1123216T1 (el) | Αναστολεις της gls1 για την αντιμετωπιση νοσων | |
CY1122818T1 (el) | Παραγωγα 3-((ετερο-)αρυλ)-αλκυλ-8-αμινο-2-οξο-1,3-διαζα- σπε1ρο-[4.5]-δεκανιου | |
CY1123366T1 (el) | Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου | |
CY1114757T1 (el) | Παραγωγα οξαζινης και η χρηση τους στη θεραπεια νευρολογικων διαταραχων | |
CY1122882T1 (el) | Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου | |
CY1122746T1 (el) | Ιατρικες αγωγες με βαση την αναμορελινη | |
CY1122474T1 (el) | Μεθοδος διαγνωσης νευραλγιας του τριδυμου | |
BR112021019663A2 (pt) | Método para produzir microvesículas terapêuticas, composição probiótica, microvesículas terapêuticas, e, cepa bacteriana | |
EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
EA202190281A1 (ru) | Производные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диаза-спиро[4,5]декана | |
BR112018012237A2 (pt) | conjugados oligonucleotídeos-peptídeos | |
CY1119308T1 (el) | Συνδυασμοι με ενα πεπτιδιο κυκλοποιημενου σκελετου | |
CO2020014673A2 (es) | Selección y uso de bacterias que apoyan la melatonina para reducir el cólico del lactante | |
EA202190226A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ | |
CY1120727T1 (el) | Συνδυασμοι με ενα πεπτιδιο κυκλοποιημενου σκελετου | |
EA201650085A1 (ru) | Способ лечения опухолевого заболевания и способ селективного ингибирования роста опухолевых клеток с помощью производного хиноксалин-1,4-диоксида | |
BR112022012226A2 (pt) | Métodos, método para preparar uma forma cristalina, forma cristalina, compostos e sal | |
CR20220072A (es) | Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias |